Comparative Pharmacology
Head-to-head clinical analysis: DEXFERRUM versus MONOFERRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXFERRUM versus MONOFERRIC.
DEXFERRUM vs MONOFERRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iron replacement therapy; provides iron for hemoglobin synthesis and erythropoiesis in iron-deficiency states.
Monomeric ferric iron replaces iron stores and is incorporated into hemoglobin, myoglobin, and enzymes, supporting erythropoiesis and oxygen transport.
100 mg intravenously over 2-5 minutes; may repeat if indicated (total dose depends on iron deficit).
100-200 mg elemental iron intravenously as a single dose, repeated weekly until iron stores are replete. Typical total dose is 1-2 g.
None Documented
None Documented
Terminal elimination half-life: 2.3–3.5 hours in adults with normal renal function. Closely follows iron kinetics; clinical effect persists beyond half-life due to intracellular iron utilization.
Terminal half-life: 10-14 hours for ferric carboxymaltose core; clinical effect persists for weeks due to iron utilization
Primarily renal: ~60% as intact drug; ~20% as metabolites. Biliary/fecal: ~15% as metabolites. Unchanged drug in feces <5%.
Renal: <1% unchanged; Biliary/fecal: >99% as iron in RBC turnover and storage
Category C
Category C
Iron Supplement
Iron Supplement